双（α-呋喃甲酸根）氧钒（IV）对非糖尿病和链脲佐菌素诱导糖尿病大鼠的影响。

Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on non-diabetic and streptozotocin-diabetic rats.

作者信息

Gao Li H, Liu Wei P, Wang Bo L, Li Ling, Xie Ming J, Li Yan R, Chen Zhi H, Chen Xi Z

机构信息

Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming, PR China.

出版信息

Clin Chim Acta. 2006 Jun;368(1-2):173-8. doi: 10.1016/j.cca.2005.12.028. Epub 2006 Feb 20.

DOI:10.1016/j.cca.2005.12.028

PMID:16487949

Abstract

BACKGROUND

Bis(alpha-furancarboxylato)oxovanadium(IV) (BFOV), a new orally active anti-diabetic vanadium complex with organic agent, has been synthesized and characterized. The current study examined the stability in aqueous solution and effects of the complex on carbohydrate and lipid metabolism in non-diabetic and streptozotocin-induced diabetic rats.

METHODS

Diabetic rats were induced by a single dose injection of streptozotocin (STZ, 50 mg/kg body weight, i.p.). The rats were randomly divided into non-diabetic (control, CON), diabetic (DM) and BFOV (0.2 mmol/kg body weight)-treated, diabetic-BFOV (0.1, 0.2 and 0.4 mmol/kg body weight) groups. All substances were given intragastrically to non-diabetic and STZ-induced diabetic rats for 4 weeks. Blood glucose concentration was monitored during administration and, at the end of experiment glycosylated hemoglobin, serum insulin, lipid concentrations and glycogen content were observed.

RESULTS

Administration of BFOV to STZ-diabetic rats dose-dependently reduced blood glucose concentration when compared to diabetic rats (P<0.01), but it did not influence blood glucose in non-diabetic rats. Serum insulin concentrations were not increased in the BFOV-treated diabetic groups and, in contrast, significantly lowered in the 0.2 mmol/kg body weight BFOV-treated non-diabetic group at the end of experiment. Moreover, BFOV markedly reduced glycosylated hemoglobin concentration and improved dyslipidemia in STZ-diabetic rats, in a dose-dependent manner (P<0.05, P<0.01), but had no significant effect on non-diabetic rats.

CONCLUSION

The organic vanadium complex was found to effectively attenuate diabetic alterations in STZ-diabetic rats.

摘要

背景

双（α-呋喃甲酸根）氧钒（IV）（BFOV）是一种新型的具有口服活性的含有机配体的抗糖尿病钒配合物，已被合成并表征。本研究检测了该配合物在水溶液中的稳定性及其对非糖尿病和链脲佐菌素诱导的糖尿病大鼠碳水化合物和脂质代谢的影响。

方法

通过单次腹腔注射链脲佐菌素（STZ，50mg/kg体重）诱导糖尿病大鼠。将大鼠随机分为非糖尿病组（对照组，CON）、糖尿病组（DM）以及接受BFOV治疗的糖尿病组（0.2mmol/kg体重）、糖尿病-BFOV组（0.1、0.2和0.4mmol/kg体重）。所有物质均经胃内给予非糖尿病和STZ诱导的糖尿病大鼠，持续4周。给药期间监测血糖浓度，实验结束时观察糖化血红蛋白、血清胰岛素、脂质浓度和糖原含量。

结果

与糖尿病大鼠相比，给STZ诱导的糖尿病大鼠施用BFOV可剂量依赖性地降低血糖浓度（P<0.01），但对非糖尿病大鼠的血糖没有影响。在实验结束时，BFOV治疗的糖尿病组血清胰岛素浓度没有升高，相反，在0.2mmol/kg体重BFOV治疗的非糖尿病组中显著降低。此外，BFOV以剂量依赖性方式显著降低STZ糖尿病大鼠的糖化血红蛋白浓度并改善血脂异常（P<0.05，P<0.01），但对非糖尿病大鼠没有显著影响。